A Look at Innoviva’s (INVA) Valuation Following Strong Earnings, FDA Priority Review, and New Buyback Program
Innoviva (INVA) shares reacted after the company reported strong gains in third quarter revenue and net income, received FDA priority review for a new drug, and announced a $125 million buyback program.
See our latest analysis for Innoviva.
Innoviva’s stock has seen renewed momentum, with a 20.2% share price gain over the past month reflecting investor excitement after the company’s buyback announcement and FDA news. The one-year total shareholder return remains fairly modest at 3.4%. Longer-term holders have still enjoyed a 53% total return over three years, showing the company’s ability to build value over time as it advances new treatments and rewards shareholders.
If Innoviva’s recent progress piques your interest, you might…
